Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
putilimab
- Development stage
- Phase 2
- Lead developer
- Sinocelltech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Putilimab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, developed by SinoCellTech. As an immune checkpoint inhibitor, it functions by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are often overexpressed by tumor cells to suppress T-cell activity. By inhibiting this pathway, putilimab restores the immune system's ability to recognize and eliminate malignant cells. It is currently being evaluated in clinical trials for various advanced solid tumors, notably in combination with vibecotecotamab (an EGFR-targeting antibody-drug conjugate) for the treatment of EGFR-positive refractory advanced biliary tract malignancies.
- Other names
- putilimab普提利单抗
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on putilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on putilimab.